Your browser doesn't support javascript.
loading
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara, Dai; Lin, Ruitao; Flowers, Christopher R; Finnigan, Shanda R; Cordes, Lisa M; Fukuda, Yoko; Huang, Erich P; Rubinstein, Larry V; Nastoupil, Loretta J; Ivy, S Percy; Doroshow, James H; Takebe, Naoko.
Afiliação
  • Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: dchihara@mdanderson.org.
  • Lin R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Finnigan SR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Fukuda Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rubinstein LV; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: takeben@mail.nih.gov.
Lancet ; 400(10351): 512-521, 2022 08 13.
Article em En | MEDLINE | ID: mdl-35964611
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Antineoplásicos Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article